18:51 , May 15, 2019 |  BC Extra  |  Company News

Vertex moving into protein degradation with Kymera collaboration

In another move to expand its suite of modalities to address serious diseases, Vertex has partnered with Kymera to develop targeted small molecule protein degraders under a four-year deal. Kymera Therapeutics LLC (Cambridge, Mass.) will...
01:14 , Jan 25, 2019 |  BC Week In Review  |  Company News

Vertex builds CRISPR toolbox with Merck KGaA deal

In its latest move to build its gene editing capabilities, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in-licensed from Merck KGaA (Xetra:MRK) rights to two DNA damage response (DDR) inhibitors for gene editing applications. While Merck has been...
19:57 , Jan 24, 2019 |  BC Extra  |  Company News

Vertex builds CRISPR toolbox with Merck KGaA deal

In its latest move to build its gene editing capabilities, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in-licensed from Merck KGaA (Xetra:MRK) rights to two DNA damage response (DDR) inhibitors for gene editing applications. While Merck has been...
03:40 , Jan 18, 2019 |  BC Innovations  |  Product R&D

Modality moves at Vertex

In licensing a suite of newly discovered gene editing tools, Vertex Pharmaceuticals Inc. is broadening its options for solving problems that its core small molecule technology can’t address. On Jan. 3, Vertex announced a deal...
16:09 , Apr 26, 2018 |  BC Innovations  |  Emerging Company Profile

Mammoth makes Dx CRISPR

Mammoth Biosciences emerged from stealth with an exclusive license to Jennifer Doudna’s CRISPR-based diagnostics technology, which could enable faster diagnosis of a range of diseases than PCR-based sequencing and culture-based techniques and be more adaptable...
23:36 , Mar 29, 2018 |  BC Innovations  |  Tools & Techniques

Cutting-edge diagnostics

Following the splash that CRISPR has made in the world of therapeutics, academics are expanding the tool kit of Cas enzymes and finding new uses in diagnostics. Early hints suggest the technology could become competitive,...
23:49 , Mar 16, 2018 |  BC Extra  |  Preclinical News

New Cas enzyme can edit RNA, target tau

In Cell , researchers from the Salk Institute for Biological Studies discovered a new RNA-targeting CRISPR enzyme, CRISPR-associated protein 13d (Cas13d), and showed it could be used to edit the transcript of a frontotemporal dementia...
16:03 , Mar 15, 2018 |  BC Extra  |  Company News

Arbor launches with $15.6 million, new CRISPR enzyme

Arbor Biotechnologies Inc. (Cambridge, Mass.) emerged from stealth mode on Thursday with a study detailing the discovery of a new CRISPR enzyme, CRISPR-associated protein 13d (Cas13d), and a $15.6 million series A round that closed...